Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors

PURPOSE: Sorafenib, a multikinase inhibitor of Raf and several growth factor receptors, is under investigation in combination with dacarbazine, a commonly used chemotherapeutic agent for the treatment of many cancers. The current phase I study investigates the effects of sorafenib on the pharmacokin...

Descripción completa

Detalles Bibliográficos
Autores principales: Brendel, Erich, Ludwig, Matthias, Lathia, Chetan, Robert, Caroline, Ropert, Stanislas, Soria, Jean-Charles, Armand, Jean-Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2010
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123694/
https://www.ncbi.nlm.nih.gov/pubmed/20821331
http://dx.doi.org/10.1007/s00280-010-1423-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123694/
https://www.ncbi.nlm.nih.gov/pubmed/20821331
http://dx.doi.org/10.1007/s00280-010-1423-9

Ejemplares similares